Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Min, Sun Young | - |
dc.contributor.author | Byeon, Hyeong Jun | - |
dc.contributor.author | Lee, Changkyu | - |
dc.contributor.author | Seo, Jisoo | - |
dc.contributor.author | Lee, Eun Seong | - |
dc.contributor.author | Shin, Beom Soo | - |
dc.contributor.author | Choi, Han-Gon | - |
dc.contributor.author | Lee, Kang Choon | - |
dc.contributor.author | Youn, Yu Seok | - |
dc.date.accessioned | 2021-06-22T19:02:00Z | - |
dc.date.available | 2021-06-22T19:02:00Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2015-10 | - |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/16934 | - |
dc.description.abstract | Nanoparticle albumin-bound (nab (TM)) technology is an effective way of delivering hydrophobic chemotherapeutics. We developed a one-pot/one-step formulation of paclitaxel (PTX)-bound albumin nanoparticles with embedded tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/PTX HSA-NP) for the treatment of pancreatic cancer. TRAIL/PTX HSA-NPs were fabricated using a high-pressure homogenizer at a TRAIL feeding ratio of 0.2%, 1.0%, and 2.0%. TRAIL/PTX HSA-NPs were spherical and became larger in size (170-230 nm) with increasing TRAIL amount (0.2-2.0%). The loading efficiencies of PTX were in the range of similar to 86.4% and significantly low at 2.0% TRAIL (60.4%). Specifically, the inhibitory concentrations (IC50) of TRAIL (1.0 or 2.0%)/PTX HSA-NPs were >20-fold lower than that of plain PTX-HSA NP (0.032 +/- 0.06, 0.022 +/- 0.005, and 0.96 +/- 0.15 ng/ml, respectively) in pancreatic Mia Paca-2 cells. Considering TRAIL loading, bioactivity, and particle size, TRAIL(1.0%)/PTX HSA-NPs were determined as the optimal candidate for further studies. TRAIL(1.0%)/PTX HSA-NPs displayed substantially greater apoptotic activity than plain PTX HSA-NP in both FACS and TUNEL analysis. The loaded PTX and TRAIL were gradually released from the TRAIL(1.0%)/PTX HSA-NPs until similar to 24 h, which is considered to be a sufficient time for delivery to the tumor tissue. TRAIL(1.0%)/PTX HSA-NP displayed markedly more antitumor efficacy than plain PTX HSA-NP in Mia Paca-2 cell-xenografted mice in terms of tumor volume (size) and weight (213.9 mm(3) and 0.18 g vs. 1126.8 mm(3) and 0.80 g, respectively). These improved in vitro and in vivo performances were due to the combined synergistic effects of PTX and TRAIL. We believe that this TRAIL/PTX HSA-NP would have potential as a novel apoptosis-based anticancer agent. (C) 2015 Elsevier B.V. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.title | Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Han-Gon | - |
dc.identifier.doi | 10.1016/j.ijpharm.2015.08.055 | - |
dc.identifier.scopusid | 2-s2.0-84942872191 | - |
dc.identifier.wosid | 000361649300053 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF PHARMACEUTICS, v.494, no.1, pp.506 - 515 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF PHARMACEUTICS | - |
dc.citation.volume | 494 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 506 | - |
dc.citation.endPage | 515 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | APOPTOSIS-INDUCING LIGAND | - |
dc.subject.keywordPlus | IMPROVED ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | DRUG-DELIVERY SYSTEMS | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | APO2L/TRAIL | - |
dc.subject.keywordPlus | CHALLENGES | - |
dc.subject.keywordAuthor | Albumin | - |
dc.subject.keywordAuthor | Nanoparticles | - |
dc.subject.keywordAuthor | TRAIL | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Pancreatic cancer | - |
dc.subject.keywordAuthor | Anti-cancer agent | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0378517315301538?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.